Drug Trial Radar · NCT03651128
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
386
Actual
Start
Apr 16, 2019
Primary completion
Apr 13, 2026
Study completion Apr 13, 2026
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.
Conditions
- Multiple Myeloma
Interventions
bb2121Biological
bb2121
DaratumumabDrug
Daratumumab
PomalidomideDrug
Pomalidomide
DexamethasoneDrug
Dexamethasone
BortezomibDrug
Bortezomib
IxazomibDrug
Ixazomib
LenalidomideDrug
Lenalidomide
CarfilzomibDrug
Carfilzomib
ElotuzumabDrug
Elotuzumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Minimum of 5 years from randomization
Locations
62 sites in 13 countries. Site status is shown where the registry gives one.
Local Institution - 109
Birmingham, Alabama
Local Institution - 141
Scottsdale, Arizona
Local Institution - 145
Los Angeles, California
Local Institution - 122
Los Angeles, California
Local Institution - 124
Palo Alto, California
Local Institution - 142
Aurora, Colorado
Local Institution - 108
Jacksonville, Florida
Local Institution - 102
Tampa, Florida
Local Institution - 131
Atlanta, Georgia
Local Institution - 140
Atlanta, Georgia
Local Institution - 139
Chicago, Illinois
Local Institution - 100
Indianapolis, Indiana
Local Institution - 112
Westwood, Kansas
Local Institution - 104
Baltimore, Maryland
Local Institution - 134
Boston, Massachusetts
Local Institution - 123
Boston, Massachusetts
Local Institution - 120
Ann Arbor, Michigan
Local Institution - 125
Rochester, Minnesota
Local Institution - 114
St Louis, Missouri
University Of Nebraska
Omaha, Nebraska
Local Institution - 138
Hackensack, New Jersey
Local Institution - 119
New York, New York
Local Institution - 115
New York, New York
Local Institution - 135
New York, New York
Local Institution - 113
Durham, North Carolina
Local Institution - 111
Philadelphia, Pennsylvania
Local Institution - 110
Philadelphia, Pennsylvania
Local Institution - 101
Pittsburgh, Pennsylvania
Local Institution - 106
Nashville, Tennessee
Local Institution - 118
Dallas, Texas
Local Institution - 103
Dallas, Texas
Local Institution - 132
Houston, Texas
Local Institution - 136
Salt Lake City, Utah
Local Institution - 105
Seattle, Washington
Local Institution - 107
Madison, Wisconsin
Froedtert Hospital BMT Medical College of Wisconsin
Milwaukee, Wisconsin
Local Institution - 202
Leuven, Belgium
Local Institution - 302
Calgary, Alberta, Canada
Local Institution - 303
Toronto, Ontario, Canada
Local Institution - 402
Lille, France
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.